Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?

REFERENCES

• Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. European Child and Adolescent Psychiatry 2006; 15: 141–148.
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu L . National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006; 63: 679–685.
   PubMed Web of Science ®Google Scholar
• Patel NC, Crismon ML, Hoagwood K . Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 2005; 44: 548–556.
   PubMed Web of Science ®Google Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A . Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. Journal of American Academy of Child and Adolescent Psychiatry 2002; 41: 337–343.
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA . A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–145.
   PubMed Web of Science ®Google Scholar
• Tailor AM, Peeters PH, Norat T, Vineis P, Romaguera D. An update on the prevalence of the metabolic syndrome in children and adolescents. International Journal of Pediatric Obesity. 2010; 5: 202–213.
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 2006; 45: 771–791.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Controlling the global obesity epidemic. Available fromURL: http://www.who.int/nut/obs.html 2002.
   Google Scholar
• Janssen I, Katzmarzyk PT, Srinivasa SR . Utility of childhood BMI in the prediction of adulthood disease: comparison of national and international references. Obesity Research 2005; 13: 1106–1115.
   PubMedGoogle Scholar
• Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry 2006; 51: 492–501.
   PubMed Web of Science ®Google Scholar
• Magarey AM, Daniels LA, Boulton TJ . Predicting obesity in early adulthood from childhood and parental obesity. International Journal of Obesity and Related Metabolic Disorders 2003; 27: 505–513.
   PubMed Web of Science ®Google Scholar
• Burke V. Obesity in childhood and cardiovascular risk. Clincal and Experimental Pharmacology and Physiology 2006; 33: 831–837.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, González-Blanch C, Crespo-Facorro B . Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22: 547–562.
   PubMed Web of Science ®Google Scholar
• Fleischhaker C, Heiser P, Hennighausen K . Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission 2007; 114: 273–280.
   PubMed Web of Science ®Google Scholar
• Fleischhaker C, Heiser P, Hennighausen K . Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. Journal of Child and Adolescent Psychopharmacology 2006; 16: 308–316.
   PubMedGoogle Scholar
• Shaw P, Sporn A, Gogtay N . Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry 2006; 63: 721–730.
   PubMed Web of Science ®Google Scholar
• Fraguas D, Merchán-Naranjo J, Laita P . Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry. 2008; 69: 1166–1175.
   PubMed Web of Science ®Google Scholar
• Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents. Findings from the Third National Health and Nutrition Examination Survey, 1988–1994. Archives of Pediatric Adolescent Medicine 2003: 157: 821–827.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. Journal of Clinical Psychiatry 2007; 68: 8–13.
   PubMed Web of Science ®Google Scholar
• Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioural therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2005; 66: 205–212.
   PubMed Web of Science ®Google Scholar
• Kwon JS, Choi JS, Bahk WM . Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder. A 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry 2006; 67: 547–553.
   PubMed Web of Science ®Google Scholar
• Biddle SJH, Mutrie N. Psychology of Physical Activity: Determinants, Well-being, and Interventions. London: Routledge, 2001.
   Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003; 54: 565–567.
   PubMed Web of Science ®Google Scholar
• Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. Journal of Clinical Psychiatry 2001; 62: S13–S22.
   PubMedGoogle Scholar
• Fraguas D, Kirchoff D. Pharmacogenetics of antipsychotic-induced weight gain. Medical Science Monitor 2006; 12: LE6–LE7.
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V . Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association 2009; 302: 1765–1773.
   PubMed Web of Science ®Google Scholar
• Walter G, DeLaroche A, Soh N . Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 2008; 16: 253–262.
   PubMed Web of Science ®Google Scholar
• Ellis D, Shirzadi K, Grzeskowiak L, Angley M. Development of a novel program to facilitate monitoring physical health and adverse effects in children and adolescents prescribed antipsychotic medication. Australasian Psychiatry 2008; 16: 368–369.
   PubMedGoogle Scholar
• Nguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry 2009; 17: 295–299.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 2004; 66: 51–57.
   PubMed Web of Science ®Google Scholar